Details of the Drug Reposition

General Information of This Drug (ID: DMEAOYJ)

Drug Name
Ponesimod   DMEAOYJ
Synonyms
854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple sclerosis DISB2WZI 8A40 Approved [1]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psoriasis vulgaris DIS6M7AN EA90 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2 ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health.